Q-omics provides the consensus-scored S100A8 profile across patient tissues and cancer cell-line models. S100A8 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, S100A8 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, S100A8 protein abundance shows 30,049 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, and HNSC as cancer lineages where S100A8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for S100A8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes S100A8 survival associations across molecular data types. S100A8 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible S100A8 RNA expression–survival associations across cancer types. High S100A8 expression shows unfavorable associations in KIRC, BRCA, LGG, GBM and SCLC, but favorable associations in LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify KIRC as the clearest survival context for S100A8 RNA expression.
This table summarizes S100A8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for S100A8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. S100A8 shows lower tumor expression in LIHC, KICH, HNSC and LUAD and higher tumor expression in KIRC and BLCA. The KIRC box plot shows higher S100A8 RNA expression in tumor versus normal tissue (log2 FC = +1.725, t-test p < 0.001).
This table shows molecular features associated with S100A8 in patient tissues and cancer cell lines. In patient samples, S100A8 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, S100A8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
